LONDON, April 28, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Intrexon Corporation (NYSE: XON), and PTC Therapeutics Inc. (NASDAQ: PTCT). Free research report on Celldex Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Celldex%20Therapeutics&d=28-Apr-2015&s=CLDX. On Monday, April 27, 2015, the NASDAQ Composite ended at 5,060.25, down 0.63%, the Dow Jones Industrial Average lost 0.23%, to finish the day at 18,037.97, and the S&P 500 closed at 2,108.92, down 0.41%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 844.51, down 1.76%, while the index has advanced 3.14% in the previous three months. Register for your complimentary reports at the links given below.
On Monday, shares in Celldex Therapeutics Inc. fluctuated between $25.07 and $30.24 before ending the session 15.85% lower at $25.33. The stock reported a trading volume of 5.28 million shares, much above its three months average volume of 2.19 million shares. Although, Celldex Therapeutics Inc.'s shares have declined 6.77% in the last one month, it has advanced 6.83% in the last three months and 38.79% on YTD basis. The company is trading above its 200-day moving average of $19.12. Moreover, shares of Celldex Therapeutics Inc. have a Relative Strength Index (RSI) of 62.65. Sign up and read the free notes on CLDX at:
ImmunoGen Inc.'s stock plummeted 11.04%, to close the day at $8.86. The stock recorded a trading volume of 2.91 million shares, much above its three months average volume of 1.65 million shares. The stock oscillated between $8.80 and $9.95 during the session. Over the last one month and over the past three months, ImmunoGen Inc.'s shares have surged 7.39% and 37.79%, respectively. Further, the stock has gained 45.25% since the start of this year. The company is trading above its 50-day moving average of $8.50, while the 50-day moving average is below ImmunoGen Inc.'s 200-day moving average of $9.25. Additionally, ImmunoGen Inc. has an RSI of 62.10. The complimentary notes on IMGN can be downloaded as in PDF format at:
On Monday, shares in Hemispherx Biopharma Inc. recorded a trading volume of 1.90 million shares, lower than its three months average volume of 2.01 million shares. The stock ended the day at $0.23, which was 3.75% below its previous day's closing of $0.24, and registered an intraday range of $0.23 and $0.25. Hemispherx Biopharma Inc.'s shares have advanced 2.76% in the last one month and 5.09% in the previous three months. However, the stock has declined 7.52% on YTD basis. The company is trading below its 50-day and 200-day moving averages of $0.24 and $0.27, respectively. Furthermore, shares of Hemispherx Biopharma Inc. have an RSI of 54.83. Register for free on Investor-Edge and access the latest research on HEB at:
Intrexon Corp.'s stock lost 7.35%, to close Monday's session at $40.86, after oscillating between $40.21 and $44.81. The stock recorded a trading volume of 1.47 million shares, close to its three months average volume of 1.44 million shares. Over the last three months and since the beginning of 2015, Intrexon Corp.'s shares have surged 28.17% and 48.42%, respectively. However, the stock has declined 4.98% in the last one month. The company is trading above its 200-day moving average. The stock's 50-day moving average of $43.77 is above its 200-day moving average of $28.58. Further, Intrexon Corp.'s stock has an RSI of 51.87. The complete research on XON is available for free at:
PTC Therapeutics Inc.'s stock finished Monday's session 6.58% lower at $65.84. A total of 0.99 million shares were traded, which was above its three months average volume of 0.65 million shares. The stock moved between $63.37 and $70.48 during the session. PTC Therapeutics Inc.'s shares have advanced 5.14% in the last one month and 19.80% in the previous three months. Additionally, from the beginning of 2015, the stock has gained an upside of 27.18%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $67.69 is greater than its 200-day moving average of $47.78. PTC Therapeutics Inc.'s stock has an RSI of 54.54. Free in depth research on PTCT is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.